By decreasing IL-6, STAT3, NF-κB, PGE-2, COX-2, and TNF-α levels, combining the effects of prebiotics and probiotics helps lower inflammation and inhibit cancer-promoting pathways, offering a promising strategy for CRC prevention and treatment [50]. The gene discussed is NFKB1; the disease is colorectal carcinoma.